Biggest changeThe following tables provide a reconciliation of Organic Sales Growth: Year Ended December 31, 2024 Percent change vs. the prior year period NA IPC IFP Consolidated Net Sales Growth 0.2 (3.1) (5.9) (1.8) Currency Translation 0.1 12.2 1.2 3.8 Divestitures and Business Exits 0.8 0.1 4.5 1.2 Organic Sales Growth 1.1 9.2 (0.2) 3.2 Year Ended December 31, 2023 Percent change vs. the prior year period NA IPC IFP Consolidated Net Sales Growth 4.9 (2.6) (2.9) 1.3 Currency Translation 0.3 7.9 1.8 2.8 Divestitures and Business Exits (0.2) — 3.9 0.6 Organic Sales Growth 5.0 5.3 2.8 4.7 The following table provides a reconciliation of Adjusted Gross Profit: Year Ended December 31 2024 2023 Gross Profit $ 7,180 $ 7,032 2024 Transformation Initiative 144 — Sale of Brazil Tissue and Professional Business — 15 Adjusted Gross Profit $ 7,324 $ 7,047 32 KIMBERLY-CLARK CORPORATION - 2024 Annual Report The following table provides a reconciliation of Adjusted Operating Profit: Year Ended December 31 2024 2023 Operating Profit $ 3,210 $ 2,344 2024 Transformation Initiative 456 — Sale of PPE Business (565) — Impairment of Intangible Assets 97 658 Legal Expense 39 — Sale of Brazil Tissue and Professional Business — (44) Adjusted Operating Profit $ 3,237 $ 2,958 The following table provides a reconciliation of Adjusted Earnings per Share: Year Ended December 31 2024 2023 Diluted Earnings per Share $ 7.55 $ 5.21 2024 Transformation Initiative 1.01 — Sale of PPE Business (1.34) — Impairment of Intangible Assets 0.17 1.36 Legal Expense 0.11 — Softex Tax Reserve Release (0.20) — Sale of Brazil Tissue and Professional Business — (0.08) Pension Settlements — 0.08 Adjusted Earnings per Share (a) $ 7.30 $ 6.57 (a) The non-GAAP adjustments included above are presented net of tax.
Biggest changeThe following table provides a reconciliation of Adjusted Gross Profit from continuing operations: Year Ended December 31 2025 2024 Gross Profit $ 5,923 $ 6,289 2024 Transformation Initiative 213 144 Adjusted Gross Profit $ 6,136 $ 6,433 The following table provides a reconciliation of Adjusted Operating Profit from continuing operations: Year Ended December 31 2025 2024 Operating Profit $ 2,351 $ 2,700 2024 Transformation Initiative 348 456 Kenvue Acquisition 32 — Sale of PPE Business — (565) Impairment of Intangible Assets — 97 Legal Expense — 39 Adjusted Operating Profit $ 2,731 $ 2,727 38 KIMBERLY-CLARK CORPORATION - 2025 Annual Report The following table provides a reconciliation of Adjusted Earnings per Share from continuing operations: Year Ended December 31 2025 2024 Diluted Earnings per Share $ 4.86 $ 6.41 2024 Transformation Initiative 0.86 1.01 Kenvue Acquisition 0.07 — OBBBA 0.29 — IFP Repatriated Earnings 0.04 — Sale of PPE Business — (1.34) Impairment of Intangible Assets — 0.17 Legal Expense — 0.11 Softex Tax Reserve Release — (0.20) Adjusted Earnings per Share (a) $ 6.12 $ 6.16 (a) The non-GAAP adjustments included above are presented net of tax.
(b) Represents the change in net sales excluding the impacts of currency translation and divestitures and business exits. Organic Sales Growth is a non-GAAP financial measure. See "Summary of Non-GAAP Financial Measures" below for reconciliations of our GAAP to non-GAAP measures.
(b) Represents the change in net sales excluding the impacts of currency translation and divestitures and business exits. Organic Sales Growth is a non-GAAP financial measure. See "Summary of Non-GAAP Financial Measures" below for reconciliations of our GAAP to non-GAAP measures.
Our third pillar is centered on making our enterprise stronger and faster while sharpening our portfolio focus and footprint on categories and markets with the greatest long-term potential. Our strong legacy of financial discipline supports our Powering Care growth strategy through consistent investment in our technologies and brands, sustained supply chain productivity and enhanced working capital efficiency.
Our third pillar is centered on making our enterprise stronger and faster while sharpening our portfolio focus and footprint on categories and markets with the greatest long-term potential. Our strong legacy of financial discipline supports our Powering Care strategy through consistent investment in our technologies and brands, sustained supply chain productivity and enhanced working capital efficiency.
Our capital allocation approach prioritizes capital investments to drive growth in our business, a strong and growing dividend, value accretive acquisitions that can enhance our portfolio, and allocation of excess cash flow to share repurchases. We are subject to risks and uncertainties, which can affect our business operations and financial results.
Our capital allocation approach prioritizes capital investments to drive durable growth in our business, a strong and growing dividend, value accretive acquisitions that can enhance our portfolio, and allocation of excess cash flow to share repurchases. We are subject to risks and uncertainties, which can affect our business operations and financial results.
Certain other subsidiaries have defined benefit pension plans or, in certain countries, termination pay plans covering substantially all regular employees. Our related accounting policies and account balances are discussed in Item 8, Note 8 to the consolidated financial statements.
Certain other subsidiaries have defined benefit pension plans or, in certain countries, termination pay plans covering substantially all regular employees. Our related accounting policies and account balances are discussed in Item 8, Note 9 to the Consolidated Financial Statements.
GAAP, excluding the impacts of currency translation and divestitures and business exits. • Adjusted Gross and Operating Profit, Adjusted Earnings per Share, and Adjusted Effective Tax Rate are defined as consolidated Gross Profit, Operating Profit, Diluted Earnings per Share, and Effective Tax Rate, respectively, as determined in accordance with U.S.
GAAP, excluding the impacts of currency translation and divestitures and business exits. • Adjusted Gross and Operating Profit, Adjusted Earnings per Share, and Adjusted Effective Tax Rate are defined as Gross Profit, Operating Profit, Diluted Earnings per Share, and Effective Tax Rate, respectively, as determined in accordance with U.S.
The following payments are not included in the table: • We will fund our defined benefit pension plans to meet or exceed statutory requirements and currently expect to contribute approximately $15 to these plans in 2025. • Other postretirement benefit payments are estimated using actuarial assumptions, including expected future service, to project the future obligations.
The following payments are not included in the table: • We will fund our defined benefit pension plans to meet or exceed statutory requirements and currently expect to contribute approximately $15 to these plans in 2026. • Other postretirement benefit payments are estimated using actuarial assumptions, including expected future service, to project the future obligations.
Pension expense beyond 2025 will depend on future investment p erformance, our contributions to the pension trusts, changes in discount rates and various other factors related to the covered participants in the plans. Substantially all U.S. retirees and employees have access to our unfunded health care and life insurance benefit plans.
Pension expense beyond 2026 will depend on future investment p erformance, our contributions to the pension trusts, changes in discount rates and various other factors related to the covered participants in the plans. Substantially all U.S. retirees and employees have access to our unfunded health care and life insurance benefit plans.
The discount (or settlement) rate used to determine the present value of our future U.S. pension obligation as of December 31, 2024 was based on a portfolio of high quality corporate debt securities with cash flows that largely match the expected benefit payments of the plan.
The discount (or settlement) rate used to determine the present value of our future U.S. pension obligation as of December 31, 2025 was based on a portfolio of high quality corporate debt securities with cash flows that largely match the expected benefit payments of the plan.
Our products are sold under well-known brands such as Kleenex, Scott, Huggies, Pull-Ups, Kotex and Depend.
Our products are sold under well-known, trusted brands such as Kleenex, Scott, Huggies, Pull-Ups, Kotex and Depend.
If the discount rate assumptions for these plans were reduced by 0.25%, the impact to 2025 other postretirement benefit expense and the increase in the December 31, 2024 benefit liability would not be material. • Health care cost trend rate .
If the discount rate assumptions for these plans were reduced by 0.25%, the impact to 2026 other postretirement benefit expense and the increase in the December 31, 2025 benefit liability would not be material. • Health care cost trend rate .
If the discount rate assumptions for these same plans were reduced by 0.25%, the increase in annual pension expense would not be material in 2025, and the December 31, 2024 pension liability would increase by about $50. • Other assumptions .
If the discount rate assumptions for these same plans were reduced by 0.25%, the increase in annual pension expense would not be material in 2026, and the December 31, 2025 pension liability would increase by about $50. • Other assumptions .
If the expected long-term rate of return on assets for the Principal Plans were lowered by 0.25%, the impact on annual pension expense would not be material in 2025 . • Discount rate .
If the expected long-term rate of return on assets for the Principal Plans were lowered by 0.25%, the impact on annual pension expense would not be material in 2026 . • Discount rate .
Our income tax related accounting policies, account balances and matters affecting income taxes are discussed in Item 8, Note 13 to the consolidated financial statements. • Deferred tax assets and related valuation allowances .
Our income tax related accounting policies, account balances and matters affecting income taxes are discussed in Item 8, Note 14 to the Consolidated Financial Statements. • Deferred tax assets and related valuation allowances .
Results in 2024 included a $565 million gain from the sale of our PPE business, offset by charges of $456 million related to the 2024 Transformation Initiative and $136 million from the impairment of intangible assets and litigation and regulatory matters associated with a previously exited business.
Results in the prior year included a $565 gain from the sale of our PPE business, offset by charges of $456 related to the 2024 Transformation Initiative and $136 from the impairment of intangible assets and litigation and regulatory matters associated with a previously exited business.
The assumptions used as a basis for the forward-looking statements include many estimates that, among other things, depend on the achievement of future cost savings and projected volume increases.
The assumptions used as a basis for the forward-looking statements include many estimates that, among other things, depend on the successful completion of the mergers and the achievement of future cost savings and projected volume increases.
The impact of these non-GAAP items on the Company’s effective tax rate represents the difference in the effective tax rate calculated with and without the non-GAAP adjustment on Income Before Income Taxes and Equity Interests and Provision for income taxes.
The impact of these non-GAAP items on the Company’s effective tax rate represents the difference in the effective tax rate calculated with and without the non-GAAP adjustment on Income from Continuing Operations Before Income Taxes and Equity Interests and Provision for income taxes.
See Item 8, Note 6 to the consolidated financial statements for details. Our short-term debt, which consists of U.S. commercial paper with original maturities up to 90 days and/or other similar short-term debt issued by non-U.S. subsidiaries, was $3 as of December 31, 2024 (included in debt payable within one year on the consolidated balance sheets).
See Item 8, Note 7 to the Consolidated Financial Statements for details. Our short-term debt, which consists of U.S. commercial paper with original maturities up to 90 days and/or other similar short-term debt issued by non-U.S. subsidiaries, was $282 as of December 31, 2025 (included in debt payable within one year on the Consolidated Balance Sheets).
The factors described under Item 1A, "Risk Factors" in this Annual Report on Form 10-K, or in our other SEC filings, among others, could cause our future results to differ from those expressed in any forward-looking statements made by us or on our behalf.
The factors described under Item 1A, "Risk Factors" in this Annual Report on Form 10-K, or in our other SEC filings, among others, could cause our future results to differ from those expressed in any forward-looking statements made 36 KIMBERLY-CLARK CORPORATION - 2025 Annual Report by us or on our behalf.
Cash costs are expected to be approximately half of that amount, primarily related to workforce reductions. Expected non-cash charges are primarily related to incremental depreciation and asset write-offs, including losses associated with the expected exit of certain markets.
Cash costs are expected to be approximately 60% of that amount, primarily related to workforce reductions and other program costs. Expected non-cash charges are primarily related to incremental depreciation and asset write-offs, including losses associated with the expected exit of certain markets.
There are a number of other assumptions involved in the calculation of pension expense and benefit obligations, primarily related to participant demographics and benefit elections. Pension expense for defined benefit pension plans is estimated to approximate $50 in 2025.
There are a number of other assumptions involved in the calculation of pension expense and benefit obligations, primarily related to participant demographics and benefit elections. Pension expense for defined benefit pension plans is estimated to approximate $45 in 2026.
We believe that our ability to generate cash from operations and our capacity to issue short-term and long-term debt are adequate to fund working capital, capital spending, pension contributions, share repurchases, dividends and other needs for the foreseeable future.
We believe that our ability to generate cash from operations and our capacity to issue short-term and long-term debt are adequate to fund working capital, obligations related to our 2024 Transformation Initiative, capital spending, pension contributions, share repurchases, dividends and other needs for the foreseeable future.
During 2024, we repurchased 7.2 million shares of our common stock at a cost of $1.0 billion through a broker in the open market, and paid $1.6 billion in dividends. We issue long-term debt in the public market periodically. Proceeds from the offerings are used for general corporate purposes, including repayment of maturing debt or outstanding commercial paper indebtedness.
During the current year, we repurchased 1.1 million shares of our common stock at a cost of $141 through a broker in the open market, and paid $1.7 billion in dividends. We issue long-term debt in the public market periodically. Proceeds from the offerings are used for general corporate purposes, including repayment of maturing debt or outstanding commercial paper indebtedness.
GAAP, see "Summary of Non-GAAP Financial Measures" below. Overview of Business and Recent Developments We are a global company focused on delivering products and solutions that provide better care for a better world, with manufacturing facilities in 30 countries, including our equity affiliates, and products sold in more than 175 countries and territories.
GAAP, see "Summary of Non-GAAP Financial Measures" below. Overview of Business and Recent Developments We are a global company focused on delivering essential products and solutions that solve unmet consumer needs and provide Better Care for a Better World. We have manufacturing facilities in 30 countries, including our equity affiliates, and products sold in more than 175 countries and territories.
Volatility in global consumer demand, commodity costs and foreign currency exchange rates increased significantly over the past few years and is expected to continue in the near term. Climate Change - We operate in many regions around the world where our businesses could be disrupted by climate change.
Volatility in global consumer demand, commodity costs and foreign currency exchange rates increased significantly over the past few years and is expected to continue in the near term. 27 KIMBERLY-CLARK CORPORATION - 2025 Annual Report Climate Change - We operate in many regions around the world where our businesses could be disrupted by climate change.
Changes in certain assumptions could affect pension expense and the benefit obligations, particularly the estimated long-term rate of return on plan assets and the discount rate used to calculate the obligations: 27 KIMBERLY-CLARK CORPORATION - 2024 Annual Report • Long-term rate of return on plan assets . The expected long-term rate of return is evaluated on an annual basis.
Changes in certain assumptions could affect pension expense and the benefit obligations, particularly the estimated long-term rate of return on plan assets and the discount rate used to calculate the obligations: • Long-term rate of return on plan assets . The expected long-term rate of return is evaluated on an annual basis.
Changing consumer preferences also include increased concerns in regard to post-consumer waste and packaging materials and their impact on environmental sustainability. If we experience 20 KIMBERLY-CLARK CORPORATION - 2024 Annual Report lower sales due to changes in consumer demand for our products, our earnings could decrease.
Changing consumer preferences also include increased concerns in regard to post-consumer waste and packaging materials and their impact on environmental sustainability. If we experience lower sales due to changes in consumer demand for our products, our earnings could decrease.
In determining the valuation allowances to establish against these deferred tax assets, 28 KIMBERLY-CLARK CORPORATION - 2024 Annual Report many factors are considered, including the specific taxing jurisdiction, the carryforward period, income tax strategies and forecasted earnings for the entities in each jurisdiction.
In determining the valuation allowances to establish against these deferred tax assets, many factors are considered, including the specific taxing jurisdiction, the carryforward period, income tax strategies and forecasted earnings for the entities in each jurisdiction.
The average month-end balance of short-term debt for the year ended December 31, 2024 was $5. These short-term borrowings provide supplemental funding to support our operations. The level of short-term debt generally fluctuates depending upon the amount of operating cash flows and the timing of customer receipts and payments for items such as pension contributions, dividends and income taxes.
The average month-end balance of short-term debt in the current year was $323. These short-term borrowings provide supplemental funding to support our operations, with the level of short-term debt generally fluctuating depending upon the amount of operating cash flows and the timing of customer receipts and payments for items such as pension contributions, dividends and income taxes.
Many countries have formally implemented Pillar 2, and several other countries have draft legislation to implement this framework. The insignificant impact of Pillar 2 has been included in our consolidated financial statements. We will continue to monitor and evaluate new legislation and guidance, which could change our current assessment.
Many countries have formally implemented Pillar 2, and several other countries have draft legislation to implement this framework. The implementation of Pillar 2 has not had a material impact on our Consolidated Financial Statements. We will continue to monitor and evaluate new legislation and guidance, which could change our current assessment.
(e) Includes impact of changes in product mix and marketing, research and general expenses.
(e) Includes impact of changes in product mix, marketing, research and general expenses and other (income) and expense, net.
(c) Impact of the sale of the Brazil tissue and professional business, sale of the PPE business and other exited businesses and markets in conjunction with the 2024 Transformation Initiative. (d) Includes net impact of productivity initiatives, product and supply chain investments and other changes in cost of products sold.
(c) Impact of the sale of the PPE business, the exit of the Company's private label diaper business in the United States, and other exited businesses and markets in conjunction with the 2024 Transformation Initiative. (d) Includes net impact of productivity initiatives, product and supply chain investments and other changes in cost of products sold.
Forward Looking Statements Certain matters contained in this report concerning the business outlook, including raw material, energy and other input costs, the anticipated charges and savings from the 2024 Transformation Initiative, cash flow and uses of cash, growth initiatives, innovations, marketing and other spending, net sales, anticipated currency rates and exchange risks, including the impact in Argentina and Türkiye, effective tax rate, contingencies and anticipated transactions of Kimberly-Clark, including dividends, share repurchases and pension contributions, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and are based upon management's expectations and beliefs concerning future events impacting Kimberly-Clark.
Forward Looking Statements Certain matters contained in this report concerning our plans and expectations regarding the pending Kenvue Acquisition, as defined in Item 8, Note 4 to the Consolidated Financial Statements (referred to below and within Item 1A, "Risk Factors" as the "pending mergers" or the "mergers") and the pending IFP Transaction, as defined in Item 8, Note 1 to the Consolidated Financial Statements, the business outlook, including raw material, energy and other input costs, the anticipated charges and savings from the 2024 Transformation Initiative, cash flow and uses of cash, growth initiatives, innovations, marketing and other spending, net sales, anticipated currency rates and exchange risks, including the impact in Argentina and Türkiye, effective tax rate, contingencies and anticipated transactions of Kimberly-Clark, including dividends, share repurchases and pension contributions, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and are based upon management's expectations and beliefs concerning future events impacting Kimberly-Clark.
As the business, geopolitical and regulatory environment concerning Russia evolves, we may not be able to sustain the limited manufacture and sale of our products, and our assets may be partially or fully impaired. 21 KIMBERLY-CLARK CORPORATION - 2024 Annual Report Consolidated Results of Operations The following discussion and analysis compares our consolidated net sales, operating profit and other information for 2024 with 2023.
As the business, geopolitical and regulatory environment concerning Russia evolves, we may not be able to sustain the limited manufacture and sale of our products, and our assets may be partially or fully impaired. Results of Operations Consolidated Results The following discussion and analysis compares our consolidated results of operations and other information for 2025 to 2024.
See Item 8, Note 4 to the consolidated financial statements for details. • Legal Expense - In 2024, we incurred certain costs related to litigation and regulatory matters for a previously exited business. • Softex Tax Reserve Release - In 2024, we released a reserve for an uncertain tax position related to the prior year impairment of certain Softex intangible assets. • Sale of Brazil Tissue and Professional Business - In 2023, we recognized a net benefit related to the sale of our Neve tissue brand and related consumer and professional tissue assets.
See Item 8, Note 5 to the Consolidated Financial Statements for details. • Legal Expense - In 2024, we incurred certain costs related to litigation and regulatory matters for a previously exited business. • Softex Tax Reserve Release - In 2024, we released a reserve for an uncertain tax position related to the prior year impairment of certain Softex intangible assets.
Pricing - Our net sales growth and profitability may be affected as we adjust prices to address market conditions. We adjust our product prices based on a number of variables including demand, the competitive environment, technological improvements, product innovations and changes in our raw material, distribution, energy and other input costs.
We adjust our product prices based on a number of variables including demand, the competitive environment, technological improvements, product innovations and changes in our raw material, distribution, energy and other input costs. Price changes may affect net sales, earnings and market share in the near term as the market adjusts to new pricing and other market conditions.
See Item 8, Note 3 to the consolidated financial statements for details. 31 KIMBERLY-CLARK CORPORATION - 2024 Annual Report • Impairment of Intangible Assets - In 2024 and 2023, we recognized charges related to the impairment of certain intangible assets related to Softex and Thinx.
See Item 8, Note 4 to the Consolidated Financial Statements for details. • Impairment of Intangible Assets - In 2024, we recognized charges related to the impairment of certain intangible assets related to Softex and Thinx.
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Introduction This MD&A is intended to provide investors with an understanding of our recent performance, financial condition, cash flows and future prospects.
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Introduction This MD&A is intended to provide investors with an understanding of our recent performance, financial condition, cash flows and future prospects. This discussion and analysis compares consolidated and segment results for the years ended December 31, 2025 and December 31, 2024 ("2025" and "2024", respectively).
In addition, many factors outside our control, including the risk that we are not able to realize the anticipated benefits of the 2024 Transformation Initiative (including risks related to disruptions to our business or operations or related to any delays in implementation), war in Ukraine (including the related responses of consumers, customers, and suppliers and sanctions issued by the U.S., the European Union, Russia or other countries), pandemics, epidemics, fluctuations in foreign currency exchange rates, the prices and availability of our raw materials, supply chain disruptions, disruptions in the capital and credit markets, counterparty defaults (including customers, suppliers and financial institutions with which we do business), failure to realize the expected benefits or synergies from our acquisition and disposition activity, impairment of goodwill and intangible assets and our projections of operating results and other factors that may affect our impairment testing, changes in customer preferences, severe weather conditions, regional instabilities and hostilities (including the war in Israel), government trade or similar regulatory actions, 30 KIMBERLY-CLARK CORPORATION - 2024 Annual Report potential competitive pressures on selling prices for our products, energy costs, general economic and political conditions globally and in the markets in which we do business, as well as our ability to maintain key customer relationships, could affect the realization of these estimates.
In addition, many factors outside our control, including risks and uncertainties around the pending mergers (including the risk that the anticipated benefits and synergies of the mergers may not be realized when expected or at all, the terms and scope of the expected financing in connection with the mergers may prove to be less favorable than currently expected, that the mergers may not be completed in a timely matter or at all and the risk of litigation related to the mergers), the pending IFP Transaction (including risks related to delays or failure to complete the proposed transaction, the incurrence of significant transaction and separation costs, adverse market reactions, regulatory or legal challenges, and operational disruptions), risks that we are not able to realize the anticipated benefits of the 2024 Transformation Initiative (including risks related to disruptions to our business or operations or related to any delays in implementation), war in Ukraine (including the related responses of consumers, customers, and suppliers and sanctions issued by the U.S., the European Union, Russia or other countries), government trade or similar regulatory actions (including current and potential trade and tariff actions affecting the countries where we operate and the resulting negative impacts on our supply chain, commodity costs, and consumer spending), pandemics, epidemics, fluctuations in foreign currency exchange rates, the prices and availability of our raw materials, supply chain disruptions, disruptions in the capital and credit markets, counterparty defaults (including customers, suppliers and financial institutions with which we do business), failure to realize the expected benefits or synergies from our acquisition and disposition activity, impairment of goodwill and intangible assets and our projections of operating results and other factors that may affect our impairment testing, changes in customer preferences, severe weather conditions, regional instabilities and hostilities, potential competitive pressures on selling prices for our products, energy costs, general economic and political conditions globally and in the markets in which we do business, as well as our ability to maintain key customer relationships, could affect the realization of these estimates.
The following will be discussed and analyzed: • Overview of Business • Overview of 2024 Results • Business Environment and Trends • Results of Operations and Related Information • Liquidity and Capital Resources • Summary of Non-GAAP Financial Measures 17 KIMBERLY-CLARK CORPORATION - 2024 Annual Report • Critical Accounting Estimates • Information Concerning Forward-Looking Statements Throughout this MD&A, we refer to financial measures that have not been calculated in accordance with accounting principles generally accepted in the U.S., or GAAP, and are therefore referred to as non-GAAP financial measures.
Amounts are reported in millions, except per share amounts, unless otherwise noted. 23 KIMBERLY-CLARK CORPORATION - 2025 Annual Report The following will be discussed and analyzed: • Overview of Business and Recent Developments • Business Environment and Trends • Results of Operations • Liquidity and Capital Resources Throughout this MD&A, we refer to financial measures that have not been calculated in accordance with accounting principles generally accepted in the U.S., or GAAP, and are therefore referred to as non-GAAP financial measures.
Net Sales: Drivers of the changes in net sales were: Percent Change in Net Sales Volume Mix/Other Net Price Divestitures and Business Exits (c) Currency Translation Total (a) Organic (b) 2024 versus 2023 0.8 0.4 1.9 (1.2) (3.8) (1.8) 3.2 (a) Total may not sum across due to rounding.
Drivers of the changes in segment net sales and operating profit were: Percent Change in Segment Net Sales Volume Mix/Other Net Price Divestitures and Business Exits (c) Currency Translation Total (a) Organic (b) NA 2.6 (0.5) (0.4) (3.9) (0.2) (2.4) 1.8 IPC 2.3 1.3 (2.0) (0.2) (2.3) (0.9) 1.7 Percent Change in Segment Operating Profit Volume Net Price Input Costs Other Manufacturing Costs (d) Currency Translation Other (e) Total NA 0.3 (1.7) (3.4) 0.4 (0.2) 5.0 0.4 IPC 4.7 (13.7) (13.1) 12.2 (1.4) 7.7 (3.6) (a) Total may not sum across due to rounding.
Business Environment and Trends Our results of operations have been, and we expect them to continue to be, affected by the following factors and key trends, which may cause our future results of operations to differ from our historical results discussed under “Consolidated Results of Operations.” Birth Rate Trends - Sales of our baby and child care products are highly correlated with birth rate trends.
See Item 8, Note 4 to the Consolidated Financial Statements for additional details. 26 KIMBERLY-CLARK CORPORATION - 2025 Annual Report Business Environment and Trends Our results of operations have been, and we expect them to continue to be, affected by the following factors and key trends, which may cause our future results of operations to differ from our historical results discussed under “Results of Operations.” Birth Rate Trends - Sales of our baby and child care products are highly correlated with birth rate trends.
The cash flows used in the discounted cash flow model are consistent with those we use in our internal planning, which gives consideration to actual business trends experienced and the long-term business strategy. We performed our 2024 impairment assessment of our intangible assets as of the first day of the third quarter using a qualitative assessment.
The cash flows used in the discounted cash flow model are consistent with those we use in our internal planning, which gives consideration to actual business trends experienced and the long-term business strategy.
The 2024 Transformation Initiative is intended to improve our focus on growth and reduce our structural cost base by realigning our internal operating and management structure to streamline our global supply chain and improve the efficiency of our corporate and regional overhead cost structures.
As we execute our strategy, we will reduce our structural cost base by realigning our internal operating and management structure to streamline our global supply chain and improve the efficiency of our corporate and regional overhead cost structures.
Other than discussed in Item 8, Note 4 to the consolidated financial statements, no additional impairment indicators were found to be present. New Accounting Standards See Item 8, Note 1 to the consolidated financial statements for a description of recent accounting standards and their anticipated effects on our consolidated financial statements.
New Accounting Standards See Item 8, Note 1 to the Consolidated Financial Statements for a description of recent accounting standards and their anticipated effects on our Consolidated Financial Statements.
These measures include: Organic Sales Growth, Adjusted Gross Profit, Adjusted Operating Profit, Adjusted Earnings per Share, and Adjusted Effective Tax Rate. • Organic Sales Growth is defined as the change in consolidated Net Sales, as determined in accordance with U.S.
These measures include: Organic Sales Growth, Adjusted Gross Profit, Adjusted Operating Profit, Adjusted Earnings per Share, and Adjusted Effective Tax Rate. All discussions regarding non-GAAP financial measures reflect results from our continuing operations for all periods presented. • Organic Sales Growth is defined as the change in Net Sales, as determined in accordance with U.S.
The income tax effect of these non-GAAP items is calculated based upon the tax laws and statutory income tax rates applicable in the tax jurisdiction(s) of the underlying non-GAAP adjustment.
The income tax effect of these non-GAAP items is calculated based upon the tax laws and statutory income tax rates applicable in the tax jurisdiction(s) of the underlying non-GAAP adjustment. Refer to the Adjusted Effective Tax Rate reconciliation below for the tax effect of these adjustments on the Company's reported Provision for income taxes.
We completed our required annual assessment of goodwill for impairment for all our reporting units using a qualitative assessment as of the first day of the third quarter of the year ended December 31, 2024, concluding that it was more likely than not that the fair value of each reporting unit significantly exceeded the respective carrying amounts. 29 KIMBERLY-CLARK CORPORATION - 2024 Annual Report During the fourth quarter of 2024, our internal reporting and management structure changed, resulting in the identification of three new reportable segments defined by geographic regions and product groupings.
We completed our required annual assessment of goodwill for impairment for all our reporting units using a qualitative assessment as of the first day of the third quarter of the year ended December 31, 2025, concluding that it was more likely than not that the fair value of each reporting unit significantly exceeded the respective carrying amounts.
Some of these markets have greater political, economic and currency volatility and greater vulnerability to infrastructure and labor disruptions. Volatility in these markets affects our production costs and the demand for our products and may impact our supply chain and distribution networks.
Volatility in these markets affects our production costs and the demand for our products and may impact our supply chain and distribution networks.
Proceeds from asset and business dispositions of $651 primarily reflected the sale of our PPE business while prior year proceeds of $245 primarily reflected the sale of our Brazil tissue and professional business. We expect capital spending to be approximately $1.0 to $1.2 billion in 2025, including incremental spending from the 2024 Transformation Initiative.
This change is largely due to proceeds from asset and business dispositions of $651 in the prior year, primarily from the sale of our PPE business, and increased capital spending ($1.1 billion compared to $721 in the prior year). We expect capital spending to be approximately $1.3 billion in 2026, including incremental spending from the 2024 Transformation Initiative.
Our first pillar focuses on 19 KIMBERLY-CLARK CORPORATION - 2024 Annual Report investing in our brands to enhance our competitive advantage by leveraging our best-in-class science and proprietary, category-shaping technologies for innovative product solutions that solve unmet consumer needs around the world.
Our first pillar focuses on investing in our brands to enhance our competitive advantage by leveraging our best-in-class science and proprietary, category-shaping technologies to deliver innovative product solutions that solve unmet consumer needs around the world. It also includes an emphasis on delivering breakthrough storytelling that grows category participation and brand love.
In setting these assumptions, we consider a number of factors including projected future returns by asset class relative to the target asset allocation. Actual asset allocations are regularly reviewed and they are periodically rebalanced to the targeted allocations when considered appropriate. As of December 31, 2024, the Principal Plans had cumulative unrecognized investment and actuarial losses of approximately $1.0 billion.
In setting these assumptions, we consider a number of factors including projected future returns by 33 KIMBERLY-CLARK CORPORATION - 2025 Annual Report asset class relative to the target asset allocation. Actual asset allocations are regularly reviewed and they are periodically rebalanced to the targeted allocations when considered appropriate.
Intangible assets that are deemed to have finite lives are amortized over their useful lives, generally ranging from 4 to 20 years. We typically obtain the assistance of third-party valuation specialists to measure the acquisition date fair values of goodwill and other intangible assets acquired.
We typically obtain the assistance of third-party valuation specialists to measure the acquisition date fair values of goodwill and other intangible assets acquired.
We do not intend to distribute any remaining foreign earnings and therefore have not recorded deferred taxes for foreign and U.S. income taxes on such earnings. We consider any excess of the amount for financial reporting over the tax basis in our foreign subsidiaries to be indefinitely reinvested.
We consider any excess of the amount for financial reporting over the tax basis in our foreign subsidiaries to be indefinitely reinvested. The determination of deferred tax liabilities on the amount of financial reporting over tax basis or the remaining foreign earnings is not practicable. • Uncertain tax positions .
A valuation allowance is recognized if, based on the weight of available evidence, it is more likely than not that some portion or all of the deferred tax asset will not be realized. • Undistributed earnings . A s of December 31, 2024, we have accumulated undistributed earnings generated by our foreign subsidiaries of approximately $10.6 billion.
A valuation allowance is recognized 34 KIMBERLY-CLARK CORPORATION - 2025 Annual Report if, based on the weight of available evidence, it is more likely than not that some portion or all of the deferred tax asset will not be realized. • Undistributed earnings .
We incurred divestiture-related costs of $30 pre-tax which were recorded in Cost of products sold and Marketing, research and general expenses, resulting in a net benefit of $44 pre-tax ($26 after-tax). See Item 8, Note 3 to the consolidated financial statements for additional details.
Upon closure of the transaction, a gain of $74 pre-tax was recognized in Other (income) and expense, net. We incurred divestiture-related costs of $30 pre-tax which were recorded in Cost of products sold and Marketing, research and general expenses, resulting in a net benefit of $44 pre-tax ($26 after-tax).
While we saw stabilization in input costs in 2024 with tailwinds in fiber, resin and energy, the overall cost basket remains elevated versus pre-pandemic levels. In 2025, we expect net input costs to be inflationary, including the impact from currency on our non-U.S. operations.
To remain competitive on our operating structure, we continue to work on programs to expand our profitability, including our 2024 Transformation Initiative. While we saw stabilization in input costs in 2025 with tailwinds in fiber, resin and energy, the overall cost basket remains elevated versus pre-pandemic levels.
Excluding these items, adjusted operating profit was $3.2 billion in 2024 and $3.0 billion in 2023. 22 KIMBERLY-CLARK CORPORATION - 2024 Annual Report Drivers of the changes in adjusted operating profit were: Percent Change in Adjusted Operating Profit Volume Net Price Input Costs Other Manufacturing Costs Currency Translation Other (a) Total (b) 2024 versus 2023 1.6 13.5 (5.8) 9.0 (6.2) (2.7) 9.4 (a) Includes impact of changes in product mix and marketing, research and general expenses.
Drivers of the changes in adjusted operating profit were: Percent Change in Adjusted Operating Profit Volume Net Price Input Costs Other Manufacturing Costs (a) Currency Translation Other (b) Total (c) 2025 versus 2024 1.2 (5.8) (7.2) 3.6 (0.6) 8.9 0.1 (a) Includes net impact of productivity initiatives, product and supply chain investments and other changes in cost of products sold.
In operating our business, we seek to: • grow our portfolio of brands through innovation, category development and commercial execution; • leverage our cost and financial discipline to fund growth and improve margins; and • allocate capital in value-creating ways. 2024 Transformation Initiative On March 27, 2024, we announced the 2024 Transformation Initiative designed to sharpen our strategic focus through a new operating model that leverages three synergistic forces: • Accelerating pioneering innovation to capture significant growth available in our categories by investing in science and technology to satisfy unmet and evolving consumer needs; • Optimizing our margin structure to deliver superior consumer propositions and implement initiatives and deploy technology and data analytics designed to create a fast, adaptable, integrated supply chain with greater visibility that can deliver continuous improvement; and • Wiring our organization for growth to drive agility, speed, and focused execution that extends our competitive advantages further into the future.
Segments are described in greater detail in Item 8, Note 16 to the Consolidated Financial Statements. 25 KIMBERLY-CLARK CORPORATION - 2025 Annual Report 2024 Transformation Initiative The 2024 Transformation Initiative is designed to sharpen our strategic focus through a new operating model and strategy that leverages three synergistic pillars: • Accelerating pioneering innovation to capture significant growth available in our product categories by investing in science-based and proprietary technology to solve unmet and evolving consumer needs, and delivering breakthrough storytelling to drive category participation and brand love; • Optimizing our margin structure to deliver superior consumer propositions at every rung of the good, better, best ladder, and implement initiatives and deploy technology and data analytics designed to create a fast, adaptable, integrated supply chain with greater visibility that can deliver continuous improvement; and • Wiring our organization for growth to drive agility, speed, and focused execution that extends our competitive advantages further into the future.
On June 1, 2023, we completed the sale transaction of our Neve tissue brand and related consumer and professional tissue assets in Brazil for $212. Upon closure of the transaction, a gain of $74 pre-tax was recognized in Other (income) and expense, net.
As the purchase of additional ownership in an already controlled subsidiary represents an equity transaction, no gain or loss was recognized in consolidated net income or comprehensive income. On June 1, 2023, we completed the sale transaction of our Neve tissue brand and related consumer and professional tissue assets in Brazil for $212.
Financing Cash used for financing for the year ended December 31, 2024 was $3.2 billion compared to $2.4 billion in the prior year. This increase was primarily due to increased share repurchases, debt repayments and dividends paid.
Financing Cash used for financing for the year ended December 31, 2025 was $2.2 billion compared to $3.2 billion in the prior year. This decrease was primarily due to decreased share repurchases, coupled with an increase in our short term debt for U.S. commercial paper.
Based upon those projections, we anticipate making annual payments for these obligations of approximately $50 through 2034. • Accrued income tax liabilities for uncertain tax positions, deferred taxes and noncontrolling interests.
Based upon those projections, we anticipate making annual payments for these obligations of approximately $45 through 2035. • Accrued income tax liabilities for uncertain tax positions, deferred taxes and noncontrolling interests. 31 KIMBERLY-CLARK CORPORATION - 2025 Annual Report Investing Cash used for investing for the year ended December 31, 2025 was $951 compared to $100 in the prior year.
Where we believe that a tax position is supportable for income tax purposes, the item is included in our income tax returns. Where treatment of a position is uncertain, a liability is recorded based upon the expected most likely outcome taking into consideration the technical merits of the position based on specific tax regulations and facts of each matter.
Where treatment of a position is uncertain, a liability is recorded based upon the expected most likely outcome taking into consideration the technical merits of the position based on specific tax regulations and facts of each matter. These liabilities may be affected by changing interpretations of laws, rulings by tax authorities or the expiration of the statute of limitations.
Results of Operations by Segment The following presents the results of the Company’s reportable segments and compares our segment net sales, operating profit and other information for 2024 with 2023 and 2023 with 2022. Certain data from prior periods presented have been recast to reflect the changes in reportable segments noted above.
Segment Results The following presents the results of the Company’s reportable segments and compares our segment net sales, operating profit and other information for 2025 to 2024.
(c) Impact of the sale of the Brazil tissue and professional business, sale of the PPE business and other exited businesses and markets in conjunction with the 2024 Transformation Initiative. Net sales of $20.1 billion for the year ended December 31, 2024 declined 1.8% primarily due to unfavorable currency impacts and divestitures and business exits.
(c) Impact of the sale of the PPE business, the exit of the Company's private label diaper business in the United States, and other exited businesses and markets in conjunction with the 2024 Transformation Initiative. Net sales of $16.4 billion declined 2.1%, primarily from divestitures and business exits and unfavorable currency impacts, partially offset by organic sales growth.
Our estimate of the fair value of our brand assets is based on a discounted cash flow model and a market-based approach using inputs which include projected revenues from our long-range plan, assumed royalty rates that could be payable if we did not own the brands, and a discount rate.
Reaching a determination on useful life requires significant judgments and assumptions regarding the future effects of obsolescence, demand, competition, other economic factors (such as the stability of the industry, known technological advances and expected changes in distribution channels), the level of required maintenance expenditures, and the expected lives of other related groups of assets. 35 KIMBERLY-CLARK CORPORATION - 2025 Annual Report Our estimate of the fair value of our brand assets is based on a discounted cash flow model and a market-based approach using inputs which include projected revenues from our long-range plan, assumed royalty rates that could be payable if we did not own the brands, and a discount rate.
Refer to the Adjusted Effective Tax Rate reconciliation below for the tax effect of these adjustments on the Company's reported Provision for income taxes. 33 KIMBERLY-CLARK CORPORATION - 2024 Annual Report The following table provides a reconciliation of the Adjusted Effective Tax Rate: Year Ended December 31 2024 2023 Income Before Income Taxes and Equity Interests Provision for Income Taxes Income Before Income Taxes and Equity Interests Provision for Income Taxes As Reported $ 2,927 $ (565) $ 2,021 $ (453) 2024 Transformation Initiative 457 (118) — — Sale of PPE Business (565) 112 — — Impairment of Intangible Assets 97 (40) 658 (175) Legal Expense 39 (1) — — Softex Tax Reserve Release — (67) — — Sale of Brazil Tissue and Professional Business — — (44) 18 Pension Settlements — — 35 (9) As Adjusted $ 2,955 $ (679) $ 2,670 $ (619) Effective Tax Rate: As Reported 19.3 % 22.4 % As Adjusted 23.0 % 23.2 %
The following table provides a reconciliation of the continuing operations Adjusted Effective Tax Rate: Year Ended December 31 2025 2024 Income From Continuing Operations Before Income Taxes and Equity Interests Provision for Income Taxes Income From Continuing Operations Before Income Taxes and Equity Interests Provision for Income Taxes As Reported $ 2,052 $ (599) $ 2,418 $ (442) 2024 Transformation Initiative 351 (56) 457 (118) Kenvue Acquisition 32 (8) — — OBBBA — 96 — — IFP Repatriated Earnings — 13 — — Sale of PPE Business — — (565) 112 Impairment of Intangible Assets — — 97 (40) Legal Expense — — 39 (1) Softex Tax Reserve Release — — — (67) As Adjusted $ 2,435 $ (554) $ 2,446 $ (556) Effective Tax Rate: As Reported 29.2 % 18.3 % As Adjusted 22.8 % 22.7 % 39 KIMBERLY-CLARK CORPORATION - 2025 Annual Report
While the global marketplace in which we operate has always been highly competitive, we continue to experience increased concentration and the growing presence of large-format retailers, discounters and e-tailers. This market environment has resulted in increased pressure on pricing and other competitive factors, and we expect these pressures to continue in the coming year.
Increased purchases of private label products could reduce net sales of our higher-margin products which would negatively impact our profitability. While the global marketplace in which we operate has always been highly competitive, we continue to experience increased concentration and the growing presence of large-format retailers, discounters and e-tailers.
These liabilities may be affected by changing interpretations of laws, rulings by tax authorities or the expiration of the statute of limitations. Goodwill and Other Intangible Assets Goodwill and other indefinite-lived intangible assets are not subject to amortization and are tested for impairment annually and whenever events or changes in circumstances indicate that impairment may have occurred.
Goodwill and Other Intangible Assets Goodwill and other indefinite-lived intangible assets are not subject to amortization and are tested for impairment annually and whenever events or changes in circumstances indicate that impairment may have occurred. Intangible assets that are deemed to have finite lives are amortized over their useful lives, generally ranging from 4 to 20 years.
We raised our dividend in 2024 by 3.4%, the 52nd consecutive annual increase in our dividend, and altogether share repurchases and dividends in 2024 amounted to $2.6 billion. In 2025, we will continue executing on our Powering Care growth strategy and its three strategic pillars: accelerate pioneering innovation, optimize our margin structure, and wire our organization for growth.
To achieve these objectives, we will continue executing our Powering Care strategy and its three synergistic, strategic pillars: accelerate pioneering innovation, optimize our margin structure, and wire our organization for growth.
Drivers of the changes in segment net sales and operating profit were: Percent Change in Segment Net Sales Volume Mix/Other Net Price Divestitures and Business Exits (c) Currency Translation Total (a) Organic (b) 2024 versus 2023 NA 0.5 0.5 0.1 (0.8) (0.1) 0.2 1.1 IPC 0.9 0.5 7.8 (0.1) (12.2) (3.1) 9.2 IFP 1.5 0.3 (2.0) (4.4) (1.2) (5.9) (0.2) 2023 versus 2022 NA 0.3 0.4 4.3 0.2 (0.3) 4.9 5.0 IPC (4.2) 1.6 7.9 — (7.9) (2.6) 5.3 IFP (7.6) 1.1 9.3 (3.9) (1.8) (2.9) 2.8 23 KIMBERLY-CLARK CORPORATION - 2024 Annual Report Percent Change in Segment Operating Profit Volume Net Price Input Costs Other Manufacturing Costs (d) Currency Translation Other (e) Total 2024 versus 2023 NA 0.9 0.4 — 1.9 (0.1) (2.0) 1.1 IPC 3.6 73.0 (33.3) 8.3 (27.8) 0.7 24.5 IFP 0.9 (25.2) 13.8 54.9 (2.7) (10.3) 31.4 2023 versus 2022 NA (0.6) 21.5 5.5 5.5 (0.3) (12.8) 18.8 IPC (7.3) 71.2 (35.7) 2.4 (16.8) (19.5) (5.7) IFP (31.9) 130.5 (46.7) (30.5) (3.5) (5.8) 12.1 (a) Total may not sum across due to rounding.
See "Summary of Non-GAAP Financial Measures" below for reconciliations of our GAAP to Non-GAAP measures. 28 KIMBERLY-CLARK CORPORATION - 2025 Annual Report Net Sales: Drivers of the changes in net sales were: Percent Change in Net Sales Volume Mix/Other Net Price Divestitures and Business Exits (c) Currency Translation Total (a) Organic (b) 2025 versus 2024 2.5 0.1 (0.9) (2.9) (0.9) (2.1) 1.7 (a) Total may not sum across due to rounding.
Year Ended December 31 2024 2023 Change 2024 vs. 2023 Net Sales $ 20,058 $ 20,431 (1.8) % Gross Profit 7,180 7,032 2.1 % Operating Profit 3,210 2,344 36.9 % Provision for income taxes (565) (453) 24.7 % Net Income Attributable to Kimberly-Clark Corporation 2,545 1,764 44.3 % Diluted Earnings per Share 7.55 5.21 44.9 % Adjusted Gross Profit (a) 7,324 7,047 3.9 % Adjusted Operating Profit (a) 3,237 2,958 9.4 % Adjusted Earnings per Share (a) 7.30 6.57 11.1 % Adjusted Effective Tax Rate (a) 23.0 % 23.2 % (0.2) % (a) Adjusted amounts are Non-GAAP financial measures.
Summary of Results Year Ended December 31 2025 2024 % Change Net Sales $ 16,447 $ 16,805 (2.1) % Gross Profit 5,923 6,289 (5.8) % Operating Profit 2,351 2,700 (12.9) % Provision for income taxes (599) (442) 35.5 % Income from Continuing Operations 1,649 2,192 (24.8) % Income from Discontinued Operations, Net of Income Taxes 400 386 3.6 % Net Income Attributable to Kimberly-Clark Corporation 2,021 2,545 (20.6) % Diluted Earnings per Share from Continuing Operations 4.86 6.41 (24.2) % Diluted Earnings per Share from Discontinued Operations 1.21 1.14 6.1 % Adjusted Results - Continuing Operations Year Ended December 31 2025 2024 % Change Adjusted Gross Profit (a) $ 6,136 $ 6,433 (4.6) % Adjusted Operating Profit (a) 2,731 2,727 0.1 % Adjusted Earnings per Share (a) 6.12 6.16 (0.6) % Adjusted Effective Tax Rate (a) 22.8 % 22.7 % 0.1 % (a) Adjusted amounts are Non-GAAP financial measures.
Acquisition and Divestiture Activity On July 1, 2024, we completed the sale transaction that was announced on April 7, 2024, of our personal protective equipment ("PPE") business for total consideration of $635, including the initial purchase price of $640 less working capital and other closing adjustments of $5.
Completed Acquisition and Divestiture Activity On July 1, 2024, we completed the sale transaction of our personal protective equipment ("PPE") business for total consideration of $635. Upon closure of the transaction, a pre-tax gain of $566 ($453 after-tax) was recognized in Other (income) and expense, net.
We believe our strategic growth focus, sustainability initiatives, innovation pipeline and continued investment in e-commerce capabilities has us well positioned relative to these changing dynamics. Volatility of Global Markets - Our growth strategy depends in part on our ability to expand our international operations, including in emerging markets.
We believe our Powering Care strategy, sharpened growth focus, sustainability initiatives, innovation pipeline and continued investment in e-commerce capabilities - underpinned by our commitment to delivering Better Care for a Better World - make us well positioned relative to these changing external dynamics.
Our competitors include global, regional and local manufacturers, including private label manufacturers which offer products that are typically sold at lower prices. In particular, private label market share has been increasing in the tissue category. Increased purchases of private label products could reduce net sales of our higher-margin products which would negatively impact our profitability.
Our competitors include global, regional and local manufacturers, including private label manufacturers which offer products that are typically sold at lower prices. In particular, we've experienced increased competitive pressures from private label manufacturers in the Baby and Child Care and Family Care categories.
(b) Adjusted Operating Profit is a non-GAAP financial measure. See "Summary of Non-GAAP Financial Measures" below for reconciliations of our GAAP to non-GAAP measures. Adjusted operating results benefited from higher adjusted gross profit discussed above, partially offset by unfavorable currency impacts, primarily due to hyperinflationary economies, and higher marketing, research and general expenses.
(b) Includes impact of changes in product mix, marketing, research and general expenses and other (income) and expense, net. (c) Adjusted Operating Profit is a non-GAAP financial measure. See "Summary of Non-GAAP Financial Measures" below for reconciliations of our GAAP to non-GAAP measures.
Earnings of $3.4 billion were previously subject to U.S. federal income tax. Any additional taxes due with respect to such previously-taxed foreign earnings, if repatriated, would generally be limited to foreign and U.S. state income taxes. Deferred taxes have been recorded on $932 of earnings of foreign consolidated subsidiaries expected to be repatriated.
Deferred taxes have been recorded on $1.2 billion of earnings of foreign consolidated subsidiaries expected to be repatriated. We do not intend to distribute any remaining foreign earnings and therefore have not recorded deferred taxes for foreign and U.S. income taxes on such earnings.
North America Year Ended December 31 % change % change 2024 2023 2022 2024 vs. 2023 2023 vs. 2022 Net Sales $ 11,008 $ 10,988 $ 10,470 0.2 % 4.9 % Operating Profit 2,534 2,507 2,110 1.1 % 18.8 % 2024 versus 2023 Net sales of $11.0 billion were flat as an increase in organic sales of 1.1% was largely offset by divestitures and business exits.
North America Year Ended December 31 2025 2024 % Change Net Sales $ 10,753 $ 11,017 (2.4) % Operating Profit 2,553 2,542 0.4 % Net sales of $10.8 billion decreased 2.4%, as the exit of the private label diaper business in the US was partially offset by organic sales growth.
Operating profit of $377 million increased 31.4% driven by gross productivity savings, partially offset by unfavorable pricing net of inflation and higher research, selling and general expenses. 2023 versus 2022 Net sales of $3.5 billion decreased 2.9% primarily due to divestitures and business exits and unfavorable currency impacts, partially offset by organic sales.
Operating profit of $796 decreased 3.6% primarily due to unfavorable pricing net of cost inflation, supply chain related investments and currency impacts, partially offset by gross productivity savings, lower marketing, research and general expenses and volume and mix gains.
Gross margin in the current year included approximately 70 basis points for charges related to the 2024 Transformation Initiative. Excluding these charges, adjusted gross margin increased 200 basis points to 36.5% primarily due to gross productivity savings from integrated margin management of approximately $500 million, favorable pricing net of inflation and volume gains, partially offset by higher manufacturing costs.
Excluding these charges, adjusted gross margin was 37.3%, a decrease of 100 basis points primarily due to unfavorable pricing net of cost inflation, including tariff impacts, and supply chain related investments, partially offset by gross productivity savings from integrated margin management of approximately $460.